# the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients

Study · id `cardio:ct-nct06653946` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06653946](<https://clinicaltrials.gov/study/NCT06653946>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06653946

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 716 participants.

## Technical summary

Registry record NCT06653946. Non-randomized; no masking; primary purpose treatment. Start 2022-07-01 (actual); primary completion 2024-07-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 716 participants (planned count; ClinicalTrials.gov record NCT06653946, source copy `cardio:ctgov-nct06653946-2024-10-29`, retrieved 2026-11-18)
- Started: 2022-07-01 (actual) (ClinicalTrials.gov record NCT06653946, source copy `cardio:ctgov-nct06653946-2024-10-29`, retrieved 2026-11-18)
- Primary completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT06653946, source copy `cardio:ctgov-nct06653946-2024-10-29`, retrieved 2026-11-18)
- Completion: 2024-11-01 (anticipated) (ClinicalTrials.gov record NCT06653946, source copy `cardio:ctgov-nct06653946-2024-10-29`, retrieved 2026-11-18)
- Countries: Egypt (ClinicalTrials.gov record NCT06653946, source copy `cardio:ctgov-nct06653946-2024-10-29`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06653946-2024-10-29`, retrieved 2026-11-18)

## The registry's words

- Brief title: the Predictors of Hemorrhagic Transformation Subtypes in Acute Embolic Stroke Patients
- Condition: Ischemic Stroke
- Condition: Alteplase Adverse Reaction
- Intervention (Drug): Alteplase
- Intervention (Drug): Alteplase
- Lead sponsor: Kafrelsheikh University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Alteplase (Activase) (`cardio:alteplase`)
- Registry lists this organization as the lead sponsor: Kafrelsheikh University (`cardio:org-kafrelsheikh-university`)

## Provenance

Content hash: 280f9c191b2606344ba9e3c42a96b39f44cf9a8f6e7d57f2f807bbbce19fbb54
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
